Physician profile
Amer Arshad
NPI 1710970652
$3,224.62
in general payments reported to CMS, 2019-2025
36 companies · $520 in 2025
The $520 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,073 · 2020: $69.98 · 2021: $241 · 2022: $586 · 2023: $345 · 2024: $388 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $688.15 | 2019-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $381.86 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $323.37 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $210.43 | 2019-2025 | |
| Abbvie INC. | $178.01 | 2022-2025 | Qulipta |
| Novartis Pharmaceuticals Corporation | $137.05 | 2019-2024 | |
| Lilly USA, LLC | $132.42 | 2019-2025 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $129.55 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $129.53 | 2019 | |
| Stimwave Technologies Incorporated | $126.00 | 2022 | |
| Amgen INC. | $102.18 | 2022-2025 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.79 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $62.15 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $61.26 | 2019-2025 | Zoryve |
| Amarin Pharma, INC. | $38.78 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $37.77 | 2025 | Tymlos |
| Teva Pharmaceuticals USA, INC. | $36.70 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $34.64 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.80 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $28.47 | 2022-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $25.45 | 2022 | |
| Eisai INC. | $25.13 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.19 | 2025 | Caplyta |
| Vertex Pharmaceuticals Incorporated | $21.04 | 2025 | |
| Merck Sharp & Dohme LLC | $19.56 | 2021 | |
| Sun Pharmaceutical Industries INC. | $17.92 | 2019 | |
| Astellas Pharma US INC | $17.76 | 2019 | |
| Allergan, INC. | $17.55 | 2020 | |
| Currax Pharmaceuticals LLC | $17.13 | 2024 | Contrave |
| Viatris Specialty LLC | $16.74 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $15.35 | 2024 | Eliquis |
| Mannkind Corporation | $15.00 | 2020 | |
| Acorda Therapeutics, INC | $13.95 | 2019 | |
| Strongbridge US INC. | $12.10 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.95 | 2022 | |
| Mylan Specialty L.P. | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Arshad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.